| The short chain fatty acid butyrate imprints an antimicrobial program in macrophages J Schulthess, S Pandey, M Capitani, KC Rue-Albrecht, I Arnold, ... Immunity 50 (2), 432-445. e7, 2019 | 768 | 2019 |
| Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model S Kirchberger, DJ Royston, O Boulard, E Thornton, F Franchini, ... Journal of Experimental Medicine 210 (5), 917-931, 2013 | 561 | 2013 |
| Emerging cytokine networks in colorectal cancer NR West, S McCuaig, F Franchini, F Powrie Nature Reviews Immunology 15 (10), 615-629, 2015 | 390 | 2015 |
| Granulocyte macrophage colony-stimulating factor-activated eosinophils promote interleukin-23 driven chronic colitis T Griseri, IC Arnold, C Pearson, T Krausgruber, C Schiering, F Franchini, ... Immunity 43 (1), 187-199, 2015 | 182 | 2015 |
| A large polysaccharide produced by Helicobacter hepaticus induces an anti-inflammatory gene signature in macrophages C Danne, G Ryzhakov, M Martínez-López, NE Ilott, F Franchini, F Cuskin, ... Cell host & microbe 22 (6), 733-745. e5, 2017 | 111 | 2017 |
| An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic K Degeling, NN Baxter, J Emery, MA Jenkins, F Franchini, P Gibbs, ... Asia‐Pacific Journal of Clinical Oncology 17 (4), 359-367, 2021 | 103 | 2021 |
| FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy JH Im, JN Buzzelli, K Jones, F Franchini, A Gordon-Weeks, B Markelc, ... Nature communications 11 (1), 4064, 2020 | 96 | 2020 |
| Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer W Cui, F Franchini, M Alexander, A Officer, HL Wong, M IJzerman, J Desai, ... Lung Cancer 146, 310-317, 2020 | 65 | 2020 |
| Alpha kinase 1 controls intestinal inflammation by suppressing the IL-12/Th1 axis G Ryzhakov, NR West, F Franchini, S Clare, NE Ilott, SN Sansom, ... Nature communications 9 (1), 3797, 2018 | 55 | 2018 |
| A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours JS Yoon-Jung Kang, Sophie O’Haire, Fanny Franchini, Maarten IJzerman, John ... Scientific Reports 12 (20495), 2022 | 24 | 2022 |
| Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... ESMO open 5 (6), e001090, 2020 | 23 | 2020 |
| Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours S O’Haire, F Franchini, YJ Kang, J Steinberg, K Canfell, J Desai, S Fox, ... Scientific reports 13 (1), 4116, 2023 | 10 | 2023 |
| Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... ESMO open 6 (5), 100224, 2021 | 10 | 2021 |
| Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes J Zhang, MJ IJzerman, J Oberoi, N Karnchanachari, RJ Bergin, ... Lung Cancer 166, 27-39, 2022 | 7 | 2022 |
| Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm S O’Haire, K Degeling, F Franchini, B Tran, SJ Luen, C Gaff, K Smith, ... Targeted Oncology 17 (5), 539-548, 2022 | 4 | 2022 |
| Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort. W Cui, F Franchini, M Alexander, A Officer, HL Wong, MJ IJzerman, ... Journal of Clinical Oncology 38 (15_suppl), e19324-e19324, 2020 | 3 | 2020 |
| Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents … A Pereira-Salgado, A Anton, F Franchini, RK Mahar, EM Kwan, S Wong, ... Expert Review of Pharmacoeconomics & Outcomes Research 23 (2), 231-239, 2023 | 2 | 2023 |
| Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach F Franchini, V Fedyashov, MJ IJzerman, K Degeling Frontiers in Pharmacology 14, 1255021, 2023 | 1 | 2023 |
| PRIMCAT-CRC: a data-driven whole disease simulation model for predicting the number of colorectal cancer patients by stage and treatment line in Australia. K Degeling, YH To, K Trapani, S Athan, P Gibbs, MJ IJzerman, F Franchini Value in Health, 2024 | | 2024 |
| Real World Treatment and Outcomes in ALK-rearranged Non-small Cell Lung Cancer; Results from a Large US-based Database G Chazan, F Franchini, R Shah, M Alexander, A John, M IJzerman, ... JTO Clinical and Research Reports, 100662, 2024 | | 2024 |
Professor Maarten IJzermanErasmus University and University of Melbourne在 unimelb.edu.au 的电子邮件经过验证
